Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

376
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
376
Inhaled Medications01:23

Inhaled Medications

631
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
631
Transcellular Transport of Solutes01:23

Transcellular Transport of Solutes

4.5K
Transcellular transport of solutes is the movement of substances like monosaccharides and amino acids through polarized cells. This transport mechanism is primarily seen in epithelial and endothelial cells aided by membrane transport proteins such as channels and transporters. The tight junctions between these cells confine the membrane proteins to the two sides of the cell. The epithelial cells have distinct apical and basolateral domains. In contrast, the endothelial cells show the luminal...
4.5K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

644
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
644
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

808
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
808
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

548
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
548

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSION.

The Journal of allergy and clinical immunology·2026
Same author

Joint modelling of wheeze and lung function from childhood to early adulthood: four population-based birth cohorts.

EClinicalMedicine·2026
Same author

Global Initiative for Asthma Updates for Diagnosing Asthma in Adults.

JAMA network open·2026
Same author

Expectations and attitudes in primary care towards home-based testing for diagnosing asthma: a mixed methods study.

BJGP open·2026
Same author

Protocol for an open labelled observational study in children & adolescents with severe asthma with an eosinophilic phenotype treated with mepolizumab (CASAM).

PloS one·2025
Same author

Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease.

PharmacoEconomics·2025

Related Experiment Video

Updated: Dec 22, 2025

Intranasal Administration of CNS Therapeutics to Awake Mice
07:15

Intranasal Administration of CNS Therapeutics to Awake Mice

Published on: April 8, 2013

61.2K

Inhaled mannitol for cystic fibrosis.

Sarah J Nevitt1, Judith Thornton2, Clare S Murray3

  • 1Department of Biostatistics, University of Liverpool, Liverpool, UK.

The Cochrane Database of Systematic Reviews
|May 3, 2020
PubMed
Summary

Inhaled dry powder mannitol improves lung function in cystic fibrosis patients compared to control. However, evidence on quality of life and comparisons with other treatments is limited, requiring further research.

More Related Videos

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice
08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

8.1K
Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD
09:47

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Published on: September 13, 2018

17.1K

Related Experiment Videos

Last Updated: Dec 22, 2025

Intranasal Administration of CNS Therapeutics to Awake Mice
07:15

Intranasal Administration of CNS Therapeutics to Awake Mice

Published on: April 8, 2013

61.2K
Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice
08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

8.1K
Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD
09:47

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Published on: September 13, 2018

17.1K

Area of Science:

  • Pulmonary Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Cystic Fibrosis (CF) patients often require airway secretion clearance.
  • Mannitol, a dry powder inhalant, offers a potentially convenient alternative to nebulized mucolytics.
  • Previous reviews have assessed mannitol's efficacy and safety in CF management.

Purpose of the Study:

  • To evaluate the tolerability of inhaled dry powder mannitol in CF patients.
  • To assess mannitol's impact on quality of life and respiratory function in CF.
  • To identify adverse events associated with mannitol treatment.

Main Methods:

  • Systematic review of randomized controlled trials comparing mannitol to placebo, active comparators, or no treatment.
  • Searched Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register.
  • Independent assessment of study inclusion, data extraction, and risk of bias; GRADE for evidence quality.

Main Results:

  • Moderate-quality evidence shows mannitol improved lung function (FEV1) over six months compared to control.
  • Low to very low-quality evidence indicated no consistent differences in quality of life.
  • Adverse events like cough and bronchospasm were reported but not significantly different between groups; comparisons with dornase alfa showed no significant differences in lung function or quality of life.

Conclusions:

  • Mannitol demonstrates moderate-quality evidence for improving lung function in CF patients over six months.
  • Low-quality evidence suggests no significant impact on quality of life.
  • Further research is needed to determine optimal use, long-term benefits, and comparative efficacy against established mucolytics.